Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
By TOM MURPHY
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.
Related Articles
-
Powell signals Federal Reserve to move slowly on interest rate cuts -
US stocks slip as Wall Street’s relentless rally takes a pause -
Mars-bound satellites arrive to KSC ahead of Blue Origin launch -
Fed rate trimmed: What does it mean for you? -
More Americans think companies benefit from legal immigration, a new poll finds
The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price Friday.
Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline develops.
Metsera Inc. has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing. Pfizer said the deal will add expertise and potential oral and injectable treatments.